Declaretimi 58 Supports Hf Benefit Of Sglt2 Inhibitors | Latest News RSS feed

Declaretimi 58 Supports Hf Benefit Of Sglt2 Inhibitors - Latest News


SGLT-2 inhibitors promising for heart failure prevention, not treatment

They also may play a role in the treatment of patients with known heart failure (HF), but further studies are required to prove definite treatment benefit ... in new users of SGLT-2 inhibitors. More r... read more

The Landmark DECLARE-TIMI 58 Cardiovascular Outcomes Trial of FARXIGA in Patients with Type 2 Diabetes to Be Featured at AHA 2018

DECLARE-TIMI 58: a landmark CVOT evaluating CV risk in patients with ... and achieved a statistically-significant reduction in the composite endpoint of hospitalization for heart failure (hHF) or CV d... read more

CANVAS PROGRAM: A road-block in the SGLT-2 inhibitor juggernaut?

The SGLT-2 inhibitor group of molecules were basking in ... Further clarifications will be available after publication oF DECLARE TIMI 58 results. Canagliflozin has MACE benefits but not any CV or all ... read more

Looking for another news?


AstraZeneca announces positive results from phase III DECLARE-TIMI 58 cardiovascular outcomes trial of Farxiga to treat type-2 diabetes

AstraZeneca announced positive results from the phase III DECLARE-TIMI 58 cardiovascular ... Dapa-HF, DELIVER and Dapa-CKD. Farxiga is a first-in-class, oral, once-daily selective inhibitor of human s... read more


Bolstering your armamentarium with SGLT2 inhibitors

The Dapagliflozin Effect on Cardiovascular Events (DECLARE-TIMI 58 ... agonists, SGLT2 inhibitors, DPP-4 inhibitors) is preferred. 41 However, other combinations may be used for those not tolerating m... read more

AstraZeneca Group plc (AZN) CEO Pascal Soriot on Q2 2018 Results - Earnings Call Transcript

Ex-US, where we have 58% of our global ... Farxiga also supports the idea that SGLT2 inhibitors in general and for CN in particular is quite potent for helping to reduce cardiovascular risk particular... read more

AstraZeneca: Farxiga Met Primary Goal In Phase III Cardiovascular Outcomes Trial

(RTTNews) - AstraZeneca Plc (AZN.L, AZN) announced Monday positive results from the Phase III DECLARE-TIMI 58 cardiovascular outcomes trial or CVOT for Farxiga (dapagliflozin), the broadest SGLT2 inhi... read more

Real world data will help AZ’s Farxiga in cardio battle

The real world data showed that three SGLT-2 inhibitors ... it will have to wait for its own DECLARE-TIMI clinical trial outcomes study, which isn’t due to report until 2019. Don't miss your daily pha... read more

Farxiga significantly reduced hospitalisation for

1 Results from DECLARE-TIMI 58, the largest SGLT2 inhibitor (SGLT2i) CVOT conducted to date, including more than 17,000 patients across 33 countries, showed that Farxiga significantly reduced the risk ... read more

Type 2 Diabetes

The SGLT-2 ... DECLARE TIMI 58 results. Canagliflozin has MACE benefits but not any CV or all-cause mortality benefits and at the cost of increased serious adverse effects. (1). Neal B. Canagliflozin ... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us